Special Issue "Transient Receptor Potential (TRP) Channels in Drug Discovery: Unlocking the Potential"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (28 February 2019)
Dr. Arpad Szallasi
Semmelweis University, Budapest, Hungary; and PILA PHARMA, Malmö, Sweden
Interests: role of TRP channels in health and disease
Dr. Sonya Lehto
Amgen, CA, USA
The molecular cloning of TRPV1 in 1997 opened up a new chapter in drug discovery efforts. According to PubMed, during the past five years more than one TRPV1 paper has been published every day (adding up to a total of 2,565), and the postulated role of TRPV1 now goes well-beyond traditional indications like chronic pain to include obesity/metabolic disorders, hypertension, cancer, or even fertility and psychiatric disorders.
An unprecedented investment by pharma into the development of TRPV1 antagonists ushered compounds into clinical trials with record speed where most flamed out due to a combination of unforeseen side-effects (most important, hyperthermia and compromised heat pain sensation) and a lack of clinical efficacy. However, with the decline of TRPV1, other TRP channels have emerged as promising therapeutic targets. At present, TRPA1, TRPV3 and V4, and TRPM8 are being tested in patients, but other TRP channels like TRPC4/C5 are probably not far behind.
In 2016, the journal Pharmaceuticals published a well-received, but admittedly incomplete collection of reviews on TRP channels as therapeutic targets (“old thoughts, new concepts”) which is now also available as an eBook. Now we invite both review articles and originals findings to be included in Volume 2 (“unlocking the potential”). Like Volume 1, this collection of manuscripts will be published first as a Special Issue in the journal, and hopefully later as an eBook. Please, email either Sonya Lehto or Arpad Szallasi if you would like to contribute a paper to this TRP channel issue.
Link for the first issue:https://www.mdpi.com/journal/pharmaceuticals/special_issues/old_concepts_new_thoughts
Dr. Arpad Szallasi
Dr. Sonya Lehto
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 850 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- TRP channels
- lung disease
- dry eye
- urinary incontinence
- thermoregulatory grooming